Podocarpusflavone A sensitizes MASLD-related hepatocellular carcinoma to lenvatinib by targeting ABAT and ALDH2
Background/aims: Despite the rising global incidence of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC), immunotherapy offers limited survival benefits in this non-viral etiology, positioning lenvatinib as a critical treatment that necessitates novel strategies to enhance its efficacy. This study aimed to identify MASLD-HCC signature genes and to explore a novel agent to overcome lenvatinib resistance. Methods: Single-cell RNA sequencing identified signature genes, validated by immunohistochemistry, qPCR, Western blot, and spatial transcriptomics in human and murine specimens. Virtual screening identified a natural compound targeting hub genes. Direct binding was confirmed using molecular dynamics simulations, cellular thermal shift assays, and surface plasmon resonance. Therapeutic efficacy and underlying mechanisms were comprehensively evaluated in vitro under lipotoxic stress conditions and in vivo using diet-induced orthotopic MASLD-HCC mouse models. Results: A 170-gene signature was established, with ABAT and ALDH2 prioritized as hub genes. Podocarpusflavone A (PCFA) emerged as a dual-targeting agent that robustly reverses acquired lenvatinib resistance. Instead of increasing protein abundance, PCFA directly binds these targets, which is accompanied by markedly enhanced cellular ABAT and ALDH activities. This diminishes the protective GABA shield and disrupts the mitochondrial NAD⁺ balance, precipitating a lethal mitochondrial superoxide burst and inhibiting key oncogenic pathways. In vivo, the PCFA and lenvatinib combination profoundly suppressed orthotopic tumor progression and was associated with short-term improvements in hepatic steatosis and fibrosis-related histological findings, with no evident toxicity under the conditions tested. Conclusions: PCFA combined with lenvatinib represents a promising strategy for MASLD-HCC and provides mechanistic insights into its antitumor activity.
Authors
- Bing Quan (ORCID: https://orcid.org/0000-0003-1821-2274)
- Zhi Dai (ORCID: https://orcid.org/0000-0002-4032-9201)
- Yufan Cai
- Yujie Shao (ORCID: https://orcid.org/0009-0002-8594-6454)
- Guiqi Zhu
- Junxian Du
- Yongjiang Lu
- Jialiang Cai
- Zhang Yan
- Peiling Zhang
- Biao Wang
- Yi Yang
- Jia Fan
- Yining Cao
- Jinghuan Li
- Shiping Chen
- Jian Zhou
Institutions
- Tongji University (CN)
- Shanghai Medical College of Fudan University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Guangzhou First People's Hospital (CN)
- Zhongshan Hospital (CN)
- Yangpu Hospital of Tongji University (CN)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3350/cmh.2026.0743
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00